These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17333516)

  • 1. Biosimilars: recent developments.
    Covic A; Kuhlmann MK
    Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are biosimilars really generics?
    Misra A
    Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues.
    Blandizzi C; Meroni PL; Lapadula G
    Clin Ther; 2017 May; 39(5):1026-1039. PubMed ID: 28416374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 12. Through the looking glass: the protein science of biosimilars.
    Goldsmith D; Kuhlmann M; Covic A
    Clin Exp Nephrol; 2007 Sep; 11(3):191-195. PubMed ID: 17891344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietins, biosimilars and immunogenicity.
    Schellekens H
    J Nephrol; 2008; 21(4):497-502. PubMed ID: 18651538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.